Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jupiter NeurosciencesJUNS -1.50%4 EV-to-EBITDA is -0.45 as of Aug. 19, 2026. GuruFocus rates JUNS with a GF Score™ of 4/100. The stock has 7 warning signs investors should review. Among 401 Biotechnology companies, Jupiter Neurosciences ranks worse than 249376.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Jupiter Neurosciences's enterprise value is $4.01 Mil.
Jupiter Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-8.93 Mil. Therefore, Jupiter Neurosciences's EV-to-EBITDA for today is -0.45.
The historical rank and industry rank for Jupiter Neurosciences's EV-to-EBITDA or its related term are showing as below:
JUNS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.89 Med: -1.73 Max: -0.34
Current: -0.45
During the past 7 years, the highest EV-to-EBITDA of Jupiter Neurosciences was -0.34. The lowest was -4.89. And the median was -1.73.
JUNS's EV-to-EBITDA is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 13.6
vs JUNS: -0.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jupiter Neurosciences's PE Ratio (TTM) for today is calculated as:
Jupiter Neurosciences's share price for today is $4.915.
Jupiter Neurosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.080.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Jupiter Neurosciences EV-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Jupiter Neurosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jupiter Neurosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jupiter Neurosciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jupiter Neurosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Jupiter Neurosciences's EV-to-EBITDA falls into.
Jupiter Neurosciences's current Enterprise Value is $4.01 Mil.
Jupiter Neurosciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.93 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jupiter Neurosciences (JUNS) has a EV-to-EBITDA of -0.45 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jupiter Neurosciences. According to the industry distribution chart, Jupiter Neurosciences ranks #999999 out of 401 companies in the Biotechnology industry.
Is Jupiter Neurosciences' EV-to-EBITDA too high?
Jupiter Neurosciences' current EV-to-EBITDA is -0.45. Based on the distribution chart, Jupiter Neurosciences ranks #999999 out of 401 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jupiter Neurosciences has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Jupiter Neurosciences' EV-to-EBITDA compare to CLGN and RNAZ?
According to the Biotechnology industry distribution chart, Jupiter Neurosciences ranks #999999 out of 401 companies for EV-to-EBITDA. This places Jupiter Neurosciences in the lower half of its industry. The industry median EV-to-EBITDA is 13.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.60, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jupiter Neurosciences. For the Biotechnology industry, the median EV-to-EBITDA is 13.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jupiter Neurosciences's current EV-to-EBITDA is -0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current EV-to-EBITDA of -0.45. The current EV-to-EBITDA is -0.45. Jupiter Neurosciences' overall GF Score™ is 4/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current EV-to-EBITDA is -0.45 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
4GF Score
Get the complete analysis for JUNS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JUNS has been successfully added to your 
